SCHEMBL4043231

SCHEMBL4043231

NC(=O)c1ccoc1CNC[C@H](O)[CH]Cc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
HSD17B10 Q99714 5/20 0.35
KDM4E B2RXH2 5/20 0.35
ALDH1A1 P00352 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
MAPT P10636 4/20 0.35
LMNA P02545 3/20 0.35
HPGD P15428 3/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
MAPK10 P53779 2/20 0.35
ALOX15 P16050 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219600 0.75 ANPEP (0.46) ALDH1A1LMNAKMT2AMEN1CYP2D6
SCHEMBL4045031 0.75 KDM1A (0.46) LMNAKMT2AMEN1SLC6A4BCHE
SCHEMBL4044662 0.74 ABCB1 (0.39) CYP2C19CYP3A4HSD17B10KDM4EALDH1A1
SCHEMBL4040582 0.74 KIT (0.39) LMNAANPEPOPRM1BCHE
SCHEMBL4047555 0.73 SIRT1 (0.38) CYP2C19HSD17B10KDM4EALDH1A1SMN1; SMN2
SCHEMBL4043818 0.72 BCHE (0.41) LMNAANPEPBCHE
SCHEMBL4049170 0.72 MPO (0.39) CYP2C19CYP3A4CYP2C9HSD17B10KDM4E
SCHEMBL4041089 0.72 MEN1 (0.35) KDM4ESMN1; SMN2KMT2AMEN1ANPEP
SCHEMBL4043224 0.71 BCHE (0.35) CYP2C19CYP2C9CYP2D6ADRB1ANPEP
SCHEMBL4039140 0.71 ABCB1 (0.47) CYP2C19HSD17B10KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612054-B2 Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2009-11-03 US disclosed
EP-1651592-B1 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2009-04-29 EP disclosed
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2007-05-17 US disclosed
EP-1651592-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2006-05-03 EP disclosed
WO-2005014517-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof APP, BACE1, BCHE CYP2C19 294/4885CYP3A4 646/4885CYP2C9 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.